89Zr-Df-crefmirlimab
- Generic Name
- 89Zr-Df-crefmirlimab
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Phase 1
Recruiting
- Conditions
- Multiple SclerosisProgressive Multifocal Leukoencephalopathy
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-02-27
- Target Recruit Count
- 10
- Registration Number
- NCT05849467
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath